In this work we propose to model chemotherapy taking into account the mutual interaction between tumour growth and the development of tumour vasculature.By adopting a simple model of this interaction,and assuming that the efficacy of a drug can be modulated by the vesse ldensity, we study the constant continuous therapy, the periodic bolus-based therapy, and combined therapy in which a chemotherapic drug is associated with an anti-angiogenic agent.The model allows to represent the vessel-disrupting activity of some standard chemotherapic drugs, and shows, in the case of constant continuous drug administration, the possibility of multiplestable equilibria.The multistability suggests an explanation for some sudden losses of control observed during therapy, and for the beneficial effect of vascular ''pruning'' exerted by anti-angiogenic agents in combined therapy.Moreover,incase of periodic therapies in which the drug amount administered per unit time is constant (''metronomic'' delivery),the model predicts a response, as a function of the bolus frequency, significantly influenced by the extent of the anti-angiogenic activity of the chemotherapic drug and by the dependence of the drug efficacy on the vessel density.
Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular "pruning"
Alberto Gandolfi
2010
Abstract
In this work we propose to model chemotherapy taking into account the mutual interaction between tumour growth and the development of tumour vasculature.By adopting a simple model of this interaction,and assuming that the efficacy of a drug can be modulated by the vesse ldensity, we study the constant continuous therapy, the periodic bolus-based therapy, and combined therapy in which a chemotherapic drug is associated with an anti-angiogenic agent.The model allows to represent the vessel-disrupting activity of some standard chemotherapic drugs, and shows, in the case of constant continuous drug administration, the possibility of multiplestable equilibria.The multistability suggests an explanation for some sudden losses of control observed during therapy, and for the beneficial effect of vascular ''pruning'' exerted by anti-angiogenic agents in combined therapy.Moreover,incase of periodic therapies in which the drug amount administered per unit time is constant (''metronomic'' delivery),the model predicts a response, as a function of the bolus frequency, significantly influenced by the extent of the anti-angiogenic activity of the chemotherapic drug and by the dependence of the drug efficacy on the vessel density.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


